ANDANJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
2/8 — Basic
DEGARELIX ACETATE (degarelix acetate) by Chia Tai TianQing Pharmaceutical Group is antagonist.
Drug data last refreshed 1mo ago
Mechanism of Action
antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Started Feb 2020
26 enrolled
Prostate Cancer
Company
Worked on DEGARELIX ACETATE at Chia Tai TianQing Pharmaceutical Group? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.